Close Menu

NEW YORK(GenomeWeb) – Qiagen said after the close of the market on Thursday that the US Food and Drug Administration cleared the artus HSV-1/2 QS-RGQ kit for molecular diagnosis of herpes simplex virus type 1 and type 2 infections.

FDA cleared the HSV-1/2 kit in late December to run on the QIAsymphony RGQ molecular diagnostics system. Qiagen said the assay was its fifth in 2014 to receive FDA clearance or approval.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.